Progress of molecular targeted therapy combined TACE of hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5782.2015.04.013

Abstract

Abstract:

For those who have not appropriate surgical removal of the middle-late hepatocellular carcinoma(HCC), simply by transcatheter arterial chemoembolization(TACE) with conventional treatment can not obviously improve the prognosis of patients.The emergence of molecular targeted drugs to treat hepatocellurlar carcinoma provides a new idea. Molecular targeted drugs in the treatment of HCC clinical trails including multiple targets inhibitors, and the targeted molecular medicine combined with TACE has shown the potential curative effect and good prospects for development.We summarize the using multiple targets inhibitors, vascular endothelial growth inhibitor combined with TACE to HCC.

Key words: Molecular-targeted drugs, Hepatocellular carcinoma, Transarterial arterial chemoembolization

Hongjin He, Heping Ma, Li Su. Progress of molecular targeted therapy combined TACE of hepatocellular carcinoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2015, 03(04): 222-225.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2015.04.013

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2015/V03/I04/222

References 31

1	Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: world-wide incidence and trends [J]. Gastroenterology, 2004, 127(5Suppl 1):S5-S16.
2	GLOBOCAN 2008[OL]. [2013-10-29]. URL
3	Liu J, Yi J. Relationship between the changes of VEGF level and dendritic cells in peripheral blood of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. J Huazhong Univ Sci Technolog Med Sci, 2007, 27(1):58-60.
4	Thomas MB,Chadha R,Glover K,et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma [J].Cancer, 2007, 110(5):1059-1067.
5	O’Dwyer PJ,Giantonio BJ,Levy DE,et al.Gefitinib in advanced unresectable hepatocelluar carcinoma:results from the Eastern Cooperative on cology Group’s Study E1203 (Meeting Abstracts) [J]. J Clin Oncol, 2006, 24:18S(abstract 4143).
6	Ramanathan RK,Belani CP,Singh DA,et al.A phaseⅡstudy of lapatinib inpatients with advanced biliary tree and hepatocellular cancer [J].Cancer Chemother Pharmacol, 2009,64(4):777-783.
7	Zhu AX,Stuart K,Blasskowsky LS,et al.Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma [J].Cancer, 2007, 110(3):581-589.
8	Schwartz JD,Schwartz M,Lehrer D,et al.Bevacizumab in unresectable hepatocellular carcinoma(HCC)for patients without metastasis and without invasion of the portalvein [J]. J Clin Oncol, 2006, 24(18):213S-213S.
9	Siegel AB,Cohen EI,Ocean A,et al.Phase Ⅱtrial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma [J].J Clin Oncol, 2008, 26(18):2992-2998.
10	Boige V,Malka D,Bourredjem A,et al.Efficacy,safety,and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma [J].Oncologist, 2012, 17(8):1063-1072.
11	Gollob JA, Wilhelm S, Carter C，et a1． Role of Raf kinasein cancer：Therapeutic potential of targeting the Raf/MEK／ERK sign altransduction pathway[J].Semin Oncol，2006,33(4):392.
12	Liu L, Cao Y, Chen C, et a1．Sorafenib blocks the RAF／MEK/ERK pathway，inhibits tumor angiogenesis，and induces tumor cell apoptosisin hepatocellular carcinoma ModelPLC/PRF/5[J].Cancer Res，2006，66(24):1185.
13	Vogl TJ, Naguib NN, Nour-Eldin NE,et al. Review on transarterial chemoembolization in hepatocel-lular carcinoma: palliative, combined,neoadjuvant,bridging, and symptomatic indications[J]. Eur J Radiol,2009,72(3):505-516.
14	Sergio A, Cristofori C, Cardin R,et al. Transcatheter arterial chemoemboliza-tion (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness[J]. Am J Gastroenterol,2008,103(4):914-921.
15	陈自谦，杨利，杨熙章, 等. 肝癌介入治疗现状与进展[J]. 介入放射学杂志，2008，17(3)223-226.
16	Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxo-rubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol,2010,33(3):541-551.
17	Takayasu K, Arii S, Ikai I,et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J].Gastroenterology,2006,131(2):461-469.
18	Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics[J]. J Hepatol,2007, 46(3):474-481.
19	Tezuka M, Hayashi K, Kubota K, et al. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma[J]. Dig Dis Sci, 2007, 52(3):783-788.
20	Georgiades CS, Hong K, D'Angelo M, et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis[J]. J Vasc Interv Radiol,2005, 16(12):1653-1659.
21	王执民，曹玮. 介入性热化疗治疗肝癌的研究现状[J]. 中国微创外科杂志, 2007, 7(7):666-667.
22	张家兴，樊树峰，郑家平, 等. 肝癌的介入性热化疗:最佳灌注温度的探讨[J]. 介入放射学杂志，2004，13(5):450-452.
23	张宁宁，饶荣生，陆伟，等．HCC伴PVTT经肝动脉-门静脉联合化疗栓塞疗效观察[J].实用肿瘤杂志，2012，20(4):253-255.
24	钱骏，Vossoughi D，OppermannE，等．血管生成抑制剂烟曲霉素衍生物在介入治疗肝细胞癌实验中的应用[J].中华放射学杂志，2006，40(1):13-15.
25	Maataoui A, Qian J, Vossoughi D，et al．Transarterial chemoembolization alone and in combination with other therapies：acomparative study in an animal HCC model [J]．Eur Radiol，2005，15(1):127-133.
26	Zhu AX, Blaszkowsky LS, Ryan DP．Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma [J]．J Clin Oncol，2006，24(12):1898-1903.
27	陈逢生，崔彦芝，罗荣城，等．索拉非尼联合顺铂对肝癌HepG-2细胞的抑制作用[J]．南方医科大学学报，2008，28:1684-1687.
28	Richly H, Schuhheis B, Adamietz IA．Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma：results from aphase extension trial [J]．Eur J Cancer，2009，45(4):579-587.
29	Takimoto CH, Awada A．Safety and anti-tumor activity of sorafenib(Nexavar) in combination with other anti-cancer agents：a review of clinical trials [J]．Cancer Chemother Pharmacol，2008，61(4):535-548.
30	Davis CR. Interventional radiological treatment of hepatocellular carcinoma[J]. Cancer Control，2010，17(1):87-99.
31	Zhang L, Fan WJ, Huang JH, et al. Comprehensive sequential interventional therapy for hepatocellular carcinoma[J]. Chin Med J (Engl) ,2009, 122(19):2292-2298.

[1]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[2]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Rongchang Wang, Qifeng Ou, Jinjie Huang, Caiqin Wang, Qian Wang, Xiaohui Huang. Expression of miR-145-5p in hepatocellular carcinoma and its clinical significance [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 197-202.
[6]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[7]	Mingxiu Ma, Feng Xu, Kailing Xie, Yaming Guo, Tonghui Lu, Chaoliu Dai. Preoperative alkaline phosphatase to prealbumin ratio predicting the prognosis of hepatocellular carcinoma after hepatectomy [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 99-103.
[8]	Qijian Yu, Zhe Yang, Shusen Zheng. Current status and progress of research on prevention of tumor recurrence after liver transplantation for hepatocellular carcinoma [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 171-179.
[9]	Yajuan Cao, Binghua Li, Decai Yu. Conversion therapy combined with robot assisted right hemihepatectomy for a patient with hepatocellular carcinoma through Laennec approach [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2023, 16(02): 116-119.
[10]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[11]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[12]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.
[13]	Zhongbai Liu, Yongjun Ren. Current status and progress of interventional therapy for hepatocellular carcinoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 111-115.
[14]	Xueqing Huang, Nan Wei, Tianpeng Jiang, Tianzhi An, Min Xu, Shi Zhou. Clinical study of TACE for hepatocellular carcinoma by ultrasound-guided transdistal radial artery approach [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(03): 251-256.
[15]	Wei Liang, Xiaobin Wang, Xiaoyang Hong, Mingyue Cai, Licong Liang, Ye Chen, Peikai Huang, Mingyu Liu, Liteng Lin, Kangshun Zhu. The establishment of recurrence model after microwave ablation in mice with orthotopic hepatocellular carcinoma [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(02): 133-139.

Please choose a citation manager

Content to export